# Elevation Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elevation-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.elevationpharma.com
- Total disclosed funding: $44M
- Latest round: Series B (Dec 20, 2011)
- Investors on record: 6

## About

Elevation Pharmaceuticals, Inc. focuses on developing and commercializing innovative therapeutic solutions for respiratory diseases, particularly enhancing medication delivery for conditions like asthma and chronic obstructive pulmonary disease (COPD).Founded in 2008 in San Diego, US, Elevation Pharmaceuticals, Inc. specializes in respiratory therapeutics. The company has engaged in three significant deals, with its most recent funding round being a Series B in December 2011, raising USD 12.40 mn from investors including Canaan Partners and TPG Growth. The company's current valuation stands at USD 70.17 mn.Elevation Pharma specializes in the development and commercialization of innovative therapeutic solutions aimed at addressing unmet medical needs in respiratory diseases. Its flagship product, a proprietary inhalation formulation, is designed to improve the delivery and effectiveness of medication for patients suffering from conditions such as asthma and chronic obstructive pulmonary disease (COPD). The formulation utilizes advanced aerosol technology, allowing for more efficient drug absorption and better patient compliance. This product is primarily targeted at hospitals, healthcare providers, and pharmacies, serving a diverse clientele that includes both direct consumers and institutional healthcare settings. Elevation Pharma's offerings are marketed in various regions, with a strong presence in North America and Europe, ensuring broad access to its targeted therapeutic solutions.The revenue structure of Elevation Pharma revolves around direct sales of its core inhalation products to healthcare providers and pharmacies, alongside potential partnerships with pharmaceutical distributors. Transactions typically occur through B2B channels, where healthcare entities place orders based on patient demand and inventory needs. The pricing strategy for its flagship inhalation formulation is structured to reflect its advanced technology and efficacy, with costs aligned to facilitate accessibility while ensuring profitability. Through established distribution agreements, Elevation Pharma maintains a steady flow of products to various healthcare institutions, enhancing its market reach and operational efficiency. The company's revenue is driven by consistent demand in the respiratory therapeutic segment, supported by ongoing clinical data that validates the effectiveness of its products.Elevation Pharmaceuticals, Inc. plans to leverage its recent funding of USD 12.40 mn raised in December 2011 to advance its product pipeline and expand market presence. The company is focused on upcoming new products in respiratory therapeutics, although specific launch dates have not been disclosed. Furthermore, Elevation is targeting expansion into new international markets, particularly in Asia and South America, with a strategic timeline for implementation in the next few years. This strategic initiative aims to enhance accessibility to their innovative inhalation solutions globally.

## Funding rounds

- Series B, Dec 20, 2011, $12M — Care Capital, TPG, Canaan Partners, Mesa Verde Venture Partners, Novo Holdings
- Series A, Sep 26, 2011, $17M — Care Capital, Canaan Partners, Mesa Verde Venture Partners, TPG Biotech
- Series A, Jan 21, 2010, $15M — Care Capital, Canaan Partners, Mesa Verde Venture Partners, TPG Biotech

## Investors

- Care Capital (https://capitalatlas.ai/funds/care-capital) — Series A, Series B
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- Mesa Verde Venture Partners (https://capitalatlas.ai/funds/mesa-verde-venture-partners) — Series A, Series B
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series A
- TPG (https://capitalatlas.ai/funds/tpg) — Series B
- Novo Holdings — Series B